(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 15.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Ocular Therapeutix's revenue in 2025 is $55,783,000.On average, 15 Wall Street analysts forecast OCUL's revenue for 2025 to be $11,939,180,331, with the lowest OCUL revenue forecast at $10,501,962,085, and the highest OCUL revenue forecast at $15,166,849,532. On average, 15 Wall Street analysts forecast OCUL's revenue for 2026 to be $13,715,144,057, with the lowest OCUL revenue forecast at $10,919,535,130, and the highest OCUL revenue forecast at $18,544,717,200.
In 2027, OCUL is forecast to generate $19,321,062,188 in revenue, with the lowest revenue forecast at $11,504,137,393 and the highest revenue forecast at $42,950,370,355.